FIELD: medicine; virology.
SUBSTANCE: developed immuno-biological agent for inducing specific immune response to Ebola virus. Agent contains human recombinant adenovirus serotype 5 containing expressing cassette with gene insertion GP Ebola virus, and human recombinant adenovirus serotype 5 containing expressing cassette with gene insertion NP Ebola virus. GP gene of Ebola virus gene is GP Ebola virus /H.sapiens-wt/SLE/2014/Makona-G3735.1 GenBank ID KM233056 with modified nucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and gene NP Ebola virus gene is NP Ebola virus /H.sapiens-wt/SLE/2014/Makona-G3735.1 GenBank ID KM233056 SEQ ID NO: 5. Immuno-biological agent additionally contains hyaluronidase. Also disclosed is method of using immuno-biological agent for inducing specific immunity to Ebola by introducing immuno-biological agent in effective amount. Presented inventions more effectively induce intensified immune response against Ebola virus in comparison with similar facilities due to features of used genetic constructs, optimising codons nucleotide sequences coding protein of Ebola virus, as well as amino acid sequences of proteins of Ebola virus.
EFFECT: presented inventions can be used in medicine as specific preventive agent for diseases caused by Ebola virus.
3 cl, 9 dwg, 2 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
IMMUNOBIOLOGICAL AGENT AND METHOD FOR USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST EBOLA VIRUS (VERSIONS) | 2015 |
|
RU2578160C1 |
STRAINS OF HYBRID CELLS OF ANIMALS MUS_ MUSCULUS - PRODUCERS OF MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE) AND MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE) | 2017 |
|
RU2686630C1 |
IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
SINGLE-DOMAIN ANTIBODIES TO EBOLA VIRUS GP PROTEIN FOR IMMUNOTHERAPY OF EBOLA FEVER | 2015 |
|
RU2644202C2 |
UNIVERSAL ANTI-INFECTIOUS VACCINE | 2015 |
|
RU2618918C2 |
ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF IMMUNE RESPONSE TO FILOVIRUSES: EBOLAVIRUS AND/OR MARBURGVIRUS, METHOD OF USING IMMUNOBIOLOGICAL AGENT | 2021 |
|
RU2760439C1 |
IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST LASSA VIRUS AND METHOD FOR USING IT | 2024 |
|
RU2823965C1 |
Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
Authors
Dates
2016-03-20—Published
2015-02-13—Filed